Clinical Trial Update: Azenosertib in Uterine Serous Carcinoma: Biomarker Study [Phase 2]

View source ↗

Summary

Phase 2 biomarker study of Azenosertib in uterine serous carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cancer
• Uterine Carcinoma
• Uterine Serous Carcinoma

Drugs mentioned

• Azenosertib (azenosertib)

Snippet

Sponsor: Joyce Liu, MD | Conditions: Uterine Serous Carcinoma, Uterine Carcinoma | Phase 2 | Status: RECRUITING